Skip to main content
Fig. 3 | Diabetology & Metabolic Syndrome

Fig. 3

From: The effect of EMPAgliflozin on markers of inflammation in patients with concomitant type 2 diabetes mellitus and Coronary ARtery Disease: the EMPA-CARD randomized controlled trial

Fig. 3

Changes in oxidative stress markers at week 26 from baseline. A significant increase observed in SOD enzyme activity, GSHr, and TAC in empagliflozin group compared to placebo, while a significant reduction observed in lymphocytic ROS (P < 0.05). SOD: Superoxidase dismutase, CAT Catalase enzyme activity, GSH Reduced Glutathione, ROS Reactive oxygen species, TAC Total antioxidant capacity, MDA Malondialdehyde

Back to article page